M&A Deal Summary

Roche Acquires Spark Therapeutics

On February 25, 2019, Roche acquired life science company Spark Therapeutics for 4.3B USD

Acquisition Highlights
  • This is Roche’s 22nd transaction in the Life Science sector.
  • This is Roche’s 5th largest (disclosed) transaction.
  • This is Roche’s 21st transaction in the United States.
  • This is Roche’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2019-02-25
Target Spark Therapeutics
Sector Life Science
Buyer(s) Roche
Deal Type Add-on Acquisition
Deal Value 4.3B USD
Advisor(s) Centerview Partners
Cowen Group, Inc. (Financial)
Goodwin Procter (Legal)

Target

Spark Therapeutics

Philadelphia, Pennsylvania, United States
Spark Therapeutics, Inc. is a gene therapy provider seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark Therapeutics was founded in 2013 and is based in Philadelphia, Pennsylvania.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 34 of 42
Sector (Life Science) 22 of 29
Type (Add-on Acquisition) 31 of 35
State (Pennsylvania) 1 of 1
Country (United States) 21 of 28
Year (2019) 1 of 3
Size (of disclosed) 5 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-28 Tusk Therapeutics

Hertfordshire, United Kingdom

Tusk Therapeutics Ltd. is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune system to transform the treatment of cancer. The Company’s lead programme consists of a first-in-class antibody for the depletion of regulatory T-cells, based on the work of Dr. Sergio Quezada.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-19 Foundation Medicine

Cambridge, Massachusetts, United States

Foundation Medicine, Inc. is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.

Buy $5.3B
Mergr

Product

Company

Legal